Theracryf Plc (TCF.L)
LSE · GBp · Healthcare · Biotechnology
£0.175 (+0.00%) as of
Key statistics
- Market cap
- 3.76M
- Forward P/E
- -2.21
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.1600 – 0.2680
- Beta
- 1.36
- Profit margin
- 0.00%
- Analyst target
- £1.19
About Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nether Alderley, United Kingdom
- Employees
- 9
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.